[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

ANI Pharma Inc (ANIP)

ANI Pharma Inc (ANIP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

ANI Pharmaceuticals Reports Tomorrow With Wall Street Already Pricing In The Cortrophin Momentum

ANI Pharmaceuticals (ANIP) reports second-quarter 2026 earnings on August 7, 2026, before market open, with analysts expecting continued momentum from the company's Rare Disease franchise and Cortrophin Gel growth. The central question is whether ANIP can sustain its remarkable streak of earnings beats—now eight consecutive quarters—while delivering on raised full-year guidance that projects revenue exceeding $1 billion for the first time. With shares trading at $82.63 against a consensus price target of $107.78, the report will test whether the company's transformation into a Rare Disease powerhouse justifies further upside.

ANI Pharmaceuticals is a specialty pharmaceutical company focused on delivering value to patients through developing,...

Fundamentals

See More
  • Market Capitalization, $K 1,779,796
  • Shares Outstanding, K 22,745
  • Annual Sales, $ 883,370 K
  • Annual Income, $ 78,340 K
  • EBIT $ 213 M
  • EBITDA $ 305 M
  • 60-Month Beta 0.44
  • Price/Sales 2.13
  • Price/Cash Flow 8.32
  • Price/Book 3.36

Options Overview Details

View History
  • Implied Volatility 33.53% (-16.74%)
  • Historical Volatility 31.33%
  • IV Percentile 1%
  • IV Rank 4.34%
  • IV High 58.60% on 02/23/26
  • IV Low 32.40% on 09/22/25
  • Expected Move (DTE 11) 1.62 (2.06%)
  • Put/Call Vol Ratio 65.47
  • Today's Volume 2,127
  • Volume Avg (30-Day) 125
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 3,734
  • Open Int (30-Day) 4,246
  • Expected Range 76.64 to 79.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $2.07
  • Number of Estimates 3
  • High Estimate $2.17
  • Low Estimate $1.94
  • Prior Year $1.64
  • Growth Rate Est. (year over year) +26.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
74.33 +5.27%
on 08/07/26
86.14 -9.16%
on 07/08/26
-7.74 (-9.00%)
since 07/07/26
3-Month
73.54 +6.40%
on 06/03/26
87.76 -10.84%
on 05/08/26
-5.66 (-6.75%)
since 05/07/26
52-Week
70.15 +11.55%
on 03/13/26
99.50 -21.36%
on 09/10/25
+9.24 (+13.39%)
since 08/07/25

Most Recent Stories

More News
ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration

ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration

ANIP : 78.25 (-5.30%)
ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2 CY2026 Sales Beat Estimates But Stock Drops On Weak Guidance

ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2 CY2026 Sales Beat Estimates But Stock Drops On Weak Guidance

ANIP : 78.25 (-5.30%)
ANI: Q2 Earnings Snapshot

ANI: Q2 Earnings Snapshot

ANIP : 78.25 (-5.30%)
ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results

Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-year Purified Cortrophin ® Gel net revenues of $117.1 million, an increase of 43.5% year-over-year ...

ANIP : 78.25 (-5.30%)
ANI Pharmaceuticals Reports Tomorrow With Wall Street Already Pricing In The Cortrophin Momentum

Barchart Research What to Expect from ANIP Earnings ANIP Generated August 6, 2026 Current Price $82.63 EPS Estimate $$1.67 Consensus Rating Strong Buy Average Move 7.23% ANI Pharmaceuticals Reports Tomorrow...

ANIP : 78.25 (-5.30%)
ANI Pharmaceuticals (ANIP) Q2 Earnings: What To Expect

ANI Pharmaceuticals (ANIP) Q2 Earnings: What To Expect

ANIP : 78.25 (-5.30%)
1 Healthcare Stock Worth Your Attention and 2 We Question

1 Healthcare Stock Worth Your Attention and 2 We Question

TECH : 72.29 (+0.54%)
LNTH : 100.95 (-0.12%)
ANIP : 78.25 (-5.30%)
ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET

PRINCETON, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results...

ANIP : 78.25 (-5.30%)
1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds

1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds

IART : 17.25 (+0.88%)
ANIP : 78.25 (-5.30%)
LH : 319.17 (+0.83%)
2 Reasons to Watch ANIP and 1 to Stay Cautious

2 Reasons to Watch ANIP and 1 to Stay Cautious

ANIP : 78.25 (-5.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone...

See More

Key Turning Points

3rd Resistance Point 84.04
2nd Resistance Point 81.32
1st Resistance Point 79.78
Last Price 78.25
1st Support Level 75.52
2nd Support Level 72.80
3rd Support Level 71.26

See More

52-Week High 99.50
Fibonacci 61.8% 88.29
Fibonacci 50% 84.82
Fibonacci 38.2% 81.36
Last Price 78.25
52-Week Low 70.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.